ROR1 and B-cell chronic lymphocytic leukemia: A phase I, single-arm, open-label trial evaluated autologous CAR-T cell therapy targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) in patients with advanced chronic lymphocytic leukemia and solid tumors (n=21) (NCT02706392).